Business
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female miceTreatment
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female miceTreatment preserved hepatic autophagy and maintained normal liver cellular homeostasisFindings support continued development of HT-VA for metabolic dysfunction associated with obesity and MASLDNEW YORK, March 10, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs, today announced new female-specific preclinical results from the second phase of its metabolic disease study evaluating glial cell-derived neurotrophic factor (GDNF).\n \n \n \n \n \n \n \nThe second phase of the study evaluated serum liver biochemistry and hepatic molecular pathways in female mice fed a western diet to model metabolic dysfunction associated with obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Results demonstrate that GDNF improved lipid metabolism biomarkers and preserved key cellular pathways in the liver compared with western diet controls and the GLP-1 agonist Semaglutide.GDNF Restores Elevated Cholesterol Levels to Control-Diet Range in Western Diet–Fed Female MiceFemale mice fed a western diet demonstrated increased serum cholesterol levels relative to control diet animals.Treatment with GDNF restored cholesterol concentrations to levels comparable with control diet-fed mice, indicating improved lipid metabolism in the diet-induced metabolic dysfunction model.GDNF Maintains Lower Triglyceride Levels While Semaglutide Increases Triglycerides in Female MiceFemale mice treated with Semaglutide while on a western diet showed increased serum triglyceride levels.In contrast, GDNF-treated western diet mice maintained lower triglyceride levels, demonstrating a more favorable lipid profile in this study.Albumin and Alkaline Phosphatase Remain Stable Across Female Treatment GroupsAnalysis of liver biochemistry markers demonstrated:No change in albumin (ALB) levels across diets or treatmentsNo significant change in alkaline phosphatase (ALP)These findings indicate liver synthetic function remained stable across female treatment groups.GDNF Preserves Hepatic Autophagy While Semaglutide Increases p62 AccumulationEvaluation of liver autophagy markers revealed:Se...